248 related articles for article (PubMed ID: 32780766)
21. Corneal squamous neoplasia: masquerades and management outcomes at a rural eyecare centre.
Agarwal A; Kaliki S; Murthy SI
BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37130635
[TBL] [Abstract][Full Text] [Related]
22. Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
Singh M; Gautam N; Kaur M
Int Ophthalmol; 2019 Feb; 39(2):295-301. PubMed ID: 29362973
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
[TBL] [Abstract][Full Text] [Related]
24. Role of high resolution optical coherence tomography in diagnosing ocular surface squamous neoplasia with coexisting ocular surface diseases.
Atallah M; Joag M; Galor A; Amescua G; Nanji A; Wang J; Perez VL; Dubovy S; Karp CL
Ocul Surf; 2017 Oct; 15(4):688-695. PubMed ID: 28347855
[TBL] [Abstract][Full Text] [Related]
25. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
Sturges A; Butt AL; Lai JE; Chodosh J
Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
[TBL] [Abstract][Full Text] [Related]
26. Chronic inflammation as a proposed risk factor for ocular surface squamous neoplasia.
De Arrigunaga S; Wall S; Theotoka D; Friehmann A; Camacho M; Dubovy S; Galor A; Karp CL
Ocul Surf; 2024 Jul; 33():1-10. PubMed ID: 38432640
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia.
Rudkin AK; Muecke JS
Br J Ophthalmol; 2011 Jul; 95(7):947-50. PubMed ID: 21252085
[TBL] [Abstract][Full Text] [Related]
28. Predictors of Ocular Surface Squamous Neoplasia and Conjunctival Squamous Cell Carcinoma among Ugandan Patients: A Hospital-based Study.
Lloyd HCM; Arunga S; Twinamasiko A; Frederick MA; Onyango J
Middle East Afr J Ophthalmol; 2018; 25(3-4):150-155. PubMed ID: 30765953
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological profile, management and clinical outcomes in recurrent cases of ocular surface squamous neoplasia at a tertiary care centre.
Kumar SV; Kumar V; Mishra SK; Sati A
Int Ophthalmol; 2023 Feb; 43(2):371-380. PubMed ID: 35857192
[TBL] [Abstract][Full Text] [Related]
30. Update on the Management of Ocular Surface Squamous Neoplasia.
Patel U; Karp CL; Dubovy SR
Curr Ophthalmol Rep; 2021 Mar; 9(1):7-15. PubMed ID: 34804642
[TBL] [Abstract][Full Text] [Related]
31. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
32. Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study.
Parrozzani R; Frizziero L; Trainiti S; Testi I; Miglionico G; Pilotto E; Blandamura S; Fassina A; Midena E
Br J Ophthalmol; 2017 Aug; 101(8):1094-1099. PubMed ID: 27941046
[TBL] [Abstract][Full Text] [Related]
33. Utility of high-resolution anterior segment optical coherence tomography in the diagnosis and management of sub-clinical ocular surface squamous neoplasia.
Tran AQ; Venkateswaran N; Galor A; Karp CL
Eye Vis (Lond); 2019; 6():27. PubMed ID: 31463333
[TBL] [Abstract][Full Text] [Related]
34. Novel automated non invasive detection of ocular surface squamous neoplasia using multispectral autofluorescence imaging.
Habibalahi A; Bala C; Allende A; Anwer AG; Goldys EM
Ocul Surf; 2019 Jul; 17(3):540-550. PubMed ID: 30904597
[TBL] [Abstract][Full Text] [Related]
35. Ocular surface squamous neoplasia: a review.
Basti S; Macsai MS
Cornea; 2003 Oct; 22(7):687-704. PubMed ID: 14508267
[TBL] [Abstract][Full Text] [Related]
36. Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis.
Kozma K; Dömötör ZR; Csutak A; Szabó L; Hegyi P; Erőss B; Helyes Z; Molnár Z; Dembrovszky F; Szalai E
Sci Rep; 2022 Aug; 12(1):14221. PubMed ID: 35987957
[TBL] [Abstract][Full Text] [Related]
37. Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature.
Kalamkar C; Radke N; Mukherjee A; Radke S
BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27166000
[TBL] [Abstract][Full Text] [Related]
38. Topical fluorouracil after surgery for ocular surface squamous neoplasia in Kenya: a randomised, double-blind, placebo-controlled trial.
Gichuhi S; Macharia E; Kabiru J; Zindamoyen AM; Rono H; Ollando E; Wachira J; Munene R; Maina J; Onyuma T; Sagoo MS; Weiss HA; Burton MJ
Lancet Glob Health; 2016 Jun; 4(6):e378-85. PubMed ID: 27198842
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interferon alpha 2b for ocular surface squamous neoplasia: An efficient and cost-effective treatment modality in Asian Indian patients.
Kaliki S; Singh S; Iram S; Tripuraneni D
Indian J Ophthalmol; 2016 Oct; 64(10):702-709. PubMed ID: 27905329
[TBL] [Abstract][Full Text] [Related]
40. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.
Wotman KL; Chow L; Martabano B; Pezzanite LM; Dow S
Cancer Immunol Immunother; 2023 May; 72(5):1185-1198. PubMed ID: 36367558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
